This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diaz-Mitoma, F.
Right arrow Articles by Huebsch, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diaz-Mitoma, F.
Right arrow Articles by Huebsch, L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, November 2003, p. 5159-5166, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5159-5166.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Comparison of DNA Amplification, mRNA Amplification, and DNA Hybridization Techniques for Detection of Cytomegalovirus in Bone Marrow Transplant Recipients

Francisco Diaz-Mitoma,1* Chantal Leger,2 Helen Miller,1 Antonio Giulivi,2,3 Rita Frost,1 Laura Shaw,1 and Lothar Huebsch2

Division of Virology, Children's Hospital of Eastern Ontario,1 Divisions of Hematology and Oncology and the Canadian Blood and Bone Marrow Transplant Program, University of Ottawa,2 Health Canada, Ottawa, Ontario, Canada3

Received 1 October 2002/ Returned for modification 5 May 2003/ Accepted 12 July 2003

A total of 676 specimens from 63 recipients of bone marrow allografts were tested for cytomegalovirus (CMV) by the following assays: CMV pp67 NucliSens (NS), AMPLICOR CMV MONITOR (RA), and the Digene CMV DNA test (DG). In a consensus analysis, the sensitivities and specificities were 60 and 99% (NS), 96 and 98% (RA), and 90 and 76% (DG), respectively; for detection of symptomatic CMV infection, they were 60 and 97% (NS), 65 and 97% (RA), and 95 and 77% (DG), respectively. In multivariate analysis, the major risk factor for symptomatic CMV infection was an increase in the viral load in the DG assay; in univariate analyses, maximum viral loads in both DG and RA assays and a rising viral load in the RA assay were also significant. The earliest detection of CMV replication was provided by the RA assay (mean, 39 days posttransplantation), followed by the DG assay (mean, 48 days) and the NS assay (mean, 58 days).

* Corresponding author. Mailing address: Division of Virology, Children's Hospital of Eastern Ontario, 401 Smyth Rd., Ottawa, ON K1H 8L1, Canada. Phone: (613) 737-7600, ext. 2736. Fax: (613) 738-4825. E-mail: diaz{at}cheo.on.ca.

Journal of Clinical Microbiology, November 2003, p. 5159-5166, Vol. 41, No. 11
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.11.5159-5166.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Marty, F. M., Bryar, J., Browne, S. K., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., Antin, J. H., Baden, L. R. (2007). Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110: 490-500 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»